Novo Nordisk A/S, the Danish producer of blockbuster weight problems medicine Ozempic and Wegovy, is planning a “mega manufacturing facility” exterior of Dublin in a bid to maintain up with hovering demand.
The pharmaceutical big has utilized to construct a campus overlaying 147,192 sq. meters (1.6 million sq. toes) in Clondalkin which might create as much as 1,100 jobs within the area, in response to reporting by the Sunday Occasions which cites detailed paperwork submitted with the planning software.
The runaway success of Ozempic and Wegovy has turned 100-year outdated Novo Nordisk into Europe’s Most worthy listed firm, with a market capitalization greater than Denmark’s home economic system. The demand has additionally examined the corporate’s manufacturing capability, and it has struggled to maintain up.
The funding will seemingly exceed €2 billion ($5.51 billion), based mostly on similar-sized developments by the corporate, the report stated. It’s going to take between 18 and 24 months to finish and needs to be totally operational by 2026.
If authorised, the Dublin growth will embody three filling and packaging manufacturing services, a warehouse constructing, two meeting and packaging services, an administration constructing and a laboratory, in response to the Sunday Occasions.
